Abstract: Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.

Abstract: Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.

Abstract: Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.

Abstract: The present invention provides polyanionic, substituted CDs having cellular growth modulating-activity. The invention further provides CDs having anionic groups on one side of the CD molecule. Therapeutic methods for using, as well as methods of making the CD compounds of the invention, are also disclosed herein.

Abstract: Anti-angiogenic protein composition can be prepared simply and efficiently by contacting cartilage particles containing the protein together with an electrolyte solution and an oligosaccharide bearing a minimum number of anionic substituents per sugar unit, to extract the anti-angiogenic protein from the cartilage particles and to form a complex of the oligosaccharide and the protein. The resultant anti-angiogenic complex can be used for therapeutic treatment of various angiogenic and related diseases.

Abstract: Disclosed are methods of therapy applicable to pathologies that involve loss of integrity of tissue and organ membranes that lead to abnormal permeation of proteinic and other agents and their elimination or penetration of other anatomical functions. Such deficiencies are associated directly or indirectly, for example, with inflammatory diseases, with diabetes and others. The therapeutic method involves administering to the membrane in need of treatment a therapeutic amount of an oligosaccharide, preferably a cyclic oligosaccharide, having up to about 10 sugar units per molecule and having at least 1.4 anionic substituents per sugar unit. The anionic substituents are preferably the residues of strong acids.

Abstract: Disclosed are compositions and methods for preventing or substantially inhibiting the hemolytic activity of hemolysis inducing agents. The methods and compositions are based on the use of an anionic oligosaccharide, such as polysulfated cyclodextrin, to achieve the desired reduction in hemolytic active inducing agents.

Abstract: The present invention provides polyanionic, substituted CDs having cellular growth modulating activity. The invention further provides CDs having anionic groups on one side of the CD molecule. Therapeutic methods for using, as well as methods of making the CD compounds of the invention, are also disclosed herein.

Abstract: Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.

Abstract: Polyionic derivatives of cyclodextrin polymers and cyclodextrins immobilized on a solid surface are disclosed. Compositions and methods for separating a molecular species, including but not limited to a biologically active protein, from a mixture, for the storage of protein factors and for the therapeutic biodelivery of protein factors which employ the polyionic derivatives of cyclodextrin polymers and cyclodextrins immobilized on a solid surface are also disclosed.

Abstract: Disclosed are compositions and methods for prevented or substantially inhibiting the hemolytic activity of hemolysis inducing agents. The methods and compositions are based on the use an anionic oligosaccharide, such as polysulfated cyclodextrin, to achieve the desired reduction in hemolytic active inducing agents.

Abstract: The invention relates to highly water soluble substituted .alpha.-, .beta.- or .gamma.-cyclodextrin sulfates associated with a physiologically acceptable cation. Pathological or otherwise undesirable cell or tissue growth in mammals, including humans, is inhibited by administering thereto (1) a water-soluble substituted cyclodextrin sulfate salt, together with (2) a growth-inhibiting organic compound. The growth-inhibiting compound (2) may be asteroid having no inhibiting effect in the absence of (1), or an organic compound which may be an active growth inhibitor, the action of which is potentiated by (1). The invention provides a method for inhibiting angiogenesis and controlling the growth of tumors as well as treating other diseases and pathological conditions associated with undesired cell or tissue growth, including angiogenesis.

Abstract: Polyionic derivatives of cyclodextrin polymers and cyclodextrins immobilized on a solid surface are disclosed. Compositions and methods for separating a molecular species, including but not limited to a biologically active protein, from a mixture, for the storage of protein factors and for the therapeutic biodelivery of protein factors which employ the polyionic derivatives of cyclodextrin polymers and cyclodextrins immobilized on a solid surface are also disclosed.

Abstract: Polyionic derivatives of cyclodextrin polymers and cyclodextrins immobilized on a solid surface are disclosed. Compositions and methods for separating a molecular species, including but not limited to a biologically active protein, from a mixture, for the storage of protein factors and for the therapeutic biodelivery of protein factors which employ the polyionic derivatives of cyclodextrin polymers and cyclodextrins immobilized on a solid surface are also disclosed.

Abstract: Pathological or otherwise undesirable cell or tissue growth in mammals, including humans, is inhibited by administering thereto a composition exemplified by (1) a water-soluble cyclodextrin sulfate salt, together with (2) a growth-inhibiting organic compound. The growth-inhibiting compound (2) may be a steroid having no inhibiting effect in the absence of (1), or an organic compound which may be an active growth inhibitor, the action of which is potentiated by (1). The invention provides a method for inhibiting angiogenesis and controlling the growth of tumors as well as treating other diseases and pathological conditions associated with undesired cell or tissue growth, including angiogenesis.

Abstract: The catalytic properties of a metal-containing shape selective crystalline silicate zeolite are significantly improved by converting said metal to an intermetallic compound. Thus, for example, zeolite beta containing the intermetallic component platinum zeolite demonstrates improved catalytic properties for dewaxing a hydrocarbon feedstock compared to zeolite beta containing platinum metal alone.

Abstract: An improved Fischer-Tropsch process for hydrocarbon synthesis operated in the fluid mode of the Sasol's Synthol Process provides increased diesel and heavier hydrocarbon yield wherein a Fischer-Tropsch synthesis catalyst modified by a minor amount of a zeolite catalyst selectively converts enough waxy product to prevent adhesion between catalyst particles which might interfere with catalyst flow thereby permitting maximization of diesel oil and heavy hydrocarbon yield.

Abstract: The catalytic properties of a metal-containing shape selective crystalline silicate zeolite are significantly improved by converting said metal to an intermetallic compound. Thus, for example, zeolite beta containing the intermetallic component platinum zeolite demonstrates improved catalytic properties for dewaxing a hydrocarbon feedstock compared to zeolite beta containing platinum metal alone.

Abstract: A process is provided for converting feedstock comprising C.sub.2.sup.+ olefins, C.sub.2 -C.sub.7 paraffins or mixtures thereof to product comprising C.sub.5.sup.+ hydrocarbons over a catalyst comprising a siliceous zeolite prepared by the method comprising providing zeolite Beta containing boron and aluminum, treating the zeolite with silicon tetrachloride at a temperature and for a time sufficient to replace boron with silicon, and recovering the siliceous zeolite having reduced boron content but substantially preserved initial aluminum content.

Abstract: A process is provided for dewaxing hydrocarbon feedstock by isomerizing the waxy components of the feedstock over catalyst comprising a siliceous zeolite having been prepared by the method comprising providing a boron-containing zeolite Beta, treating the zeolite with silicon tetrachloride at a temperature and for a time sufficient to replace boron with silicon, and recovering the siliceous zeolite having reduced boron content but substantially preserved initial aluminum content.